King Pharmaceuticals receives FDA complete response letter for CorVue NDA

Download PDF Copy

Oct 21 2009

King Pharmaceuticals, Inc. (NYSE: KG) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for CorVue™ (binodenoson) for injection. CorVue™ is a cardiac pharmacologic stress agent for use as an adjunct in SPECT (single-photon-emission computed tomographic) cardiac imaging intended for use in patients with or at risk for coronary artery disease (CAD) who are unable to perform a cardiac exercise stress test.

King is currently evaluating the FDA’s complete response letter and expects to respond to the Agency’s questions as quickly as possible.

Source:

King Pharmaceuticals, Inc.

Posted in: Medical Condition News | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

Mushrooms deliver nutrition medicine and sustainability solutions in one package

Edible microbeads trap fat to support weight loss

New treatment approach developed to prevent lupus nephritis

Hypothalamic neurons help maintain blood sugar during daily activities

New study reveals long road to seizure control for people with focal epilepsy

WHO expands global network of trusted medical product regulators

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.